509226 Sigma-AldrichPI 3-K Inhibitor XXI, GDC-0941 - CAS 957054-30-7 - Calbiochem
A cell-permeable, potent, ATP-competitive inhibitor of class IA (IC₅₀ = 3 nM/p110α, 33 nM/p110&beta, 3 nM/p110δ) and IB PI 3-kinases (IC₅₀ = 75 nM/p110γ).
More>> A cell-permeable, potent, ATP-competitive inhibitor of class IA (IC₅₀ = 3 nM/p110α, 33 nM/p110&beta, 3 nM/p110δ) and IB PI 3-kinases (IC₅₀ = 75 nM/p110γ). Less<<MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
同义词: GDC0941, 2-(1H-Indazol-4-yl)-6-(4-methylsulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d]pyrimidine, 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine
Recommended Products
概述
Replacement Information |
---|
重要规格表
CAS # | Empirical Formula |
---|---|
957054-30-7 | C₂₃H₂₇N₇O₃S₂ |
价格及供货情况
产品目录编号 | 库存情况 | 包装 | 数量 / 包装 | 价格 | 数量 | |
---|---|---|---|---|---|---|
5.09226.0001 |
|
玻璃瓶 | 10 mg |
|
— |
Product Information | |
---|---|
CAS number | 957054-30-7 |
Form | White solid |
Hill Formula | C₂₃H₂₇N₇O₃S₂ |
Chemical formula | C₂₃H₂₇N₇O₃S₂ |
Reversible | Y |
Structure formula Image | |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | PI 3-K |
Purity | ≥99% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
产品目录编号 | GTIN |
5.09226.0001 | 04055977241693 |
Documentation
PI 3-K Inhibitor XXI, GDC-0941 - CAS 957054-30-7 - Calbiochem MSDS
职位 |
---|
参考
参考信息概述 |
---|
Tabe, Y., et al. 2014. Acta Haematol. 131, 59. Ware, J.A., et al. 2013. Mol. Pharm. 10, 4047. Junttila,.T., et al. 2009. Cancer Cell 15, 429. Raynaud, F.I., et al. 2009. Mol Cancer Ther. 8, 1725. Folkes, A. J., et al. 2008. J. Med. Chem. 51, 5522. |